Chorea
Patients with unexplained chorea should be tested for antiphospholipid antibodies
Unexplained chorea, especially among women, should prompt testing for antibodies associated with antiphospholipid syndrome, according to data published in Lupus Science & Medicine.
FDA accepts new drug application for sprinkle form of Ingrezza capsules
The FDA has accepted a new drug application from Neurocrine Biosciences Inc. for its novel granule formulation of oral Ingrezza capsules, for those with tardive dyskinesia or chorea associated with Huntington’s disease.
Valbenazine improved chorea associated with Huntington’s as early as 2 weeks
A Southern California-based bioscience firm has announced additional positive data on FDA-approved Ingrezza capsules to treat adults with chorea associated with Huntington’s disease.
FDA approves Ingrezza for chorea associated with Huntington’s disease
The FDA has approved once-daily Ingrezza capsules for adults with chorea associated with Huntington’s disease.
Valbenazine well-tolerated, improved chorea associated with Huntington’s disease
Treatment with valbenazine at doses up to 80 mg once daily was generally well-tolerated and significantly improved chorea compared with placebo in adults with Huntington’s disease, according to research in The Lancet Neurology.